Testim^®

Bentley earns royalty revenues on sales of Testim, a testosterone gel that incorporates Bentley’s CPE-215 drug delivery technology. Bentley’s licensee – Auxilium Pharmaceuticals, Inc. – successfully launched Testim in the U.S. in early 2003, and it now commands approximately 19.8 percent of the U.S. testosterone gel replacement market. Testim has been approved for marketing in Canada and 15 EU countries including Belgium, Germany, Greece, Ireland, Portugal, Spain, Sweden and the United Kingdom and has received scientific approval in Italy.

Currently marketed hormone replacement therapies deliver hormones through injections, transdermal patches and gels. Injection therapy has limitations, including pain, which can lead to decreased patient acceptance and decreased compliance. Although patches have alleviated many of the gastrointestinal side effects associated with oral delivery of hormones, patches are often conspicuous and may result in skin irritation or even inaccurate dosing should the patch fall off. The transdermal delivery of hormones through gels, creams and lotions provides commercially attractive and efficacious alternatives to other current methods of delivery. Testim delivers 30 percent more testosterone than its leading competitor.

The testosterone replacement market has increased as more baby-boomers enter middle age and more attention is focused on male hormonal deficiencies. Bentley estimates that hypogonadism – a condition in men where insufficient amounts of testosterone are produced - today affects one out of every five men in the U.S. and Europe over age 50. Symptoms associated with low testosterone levels in men include depression, decreased libido, erectile dysfunction, muscular atrophy, loss of energy, mood alterations, increased body fat and reduced bone density. The condition is significantly under-treated. Growing patient awareness and education continue to spur demand for testosterone replacement therapy (TRT).

The information posted is as of 06/29/07 and, to our knowledge, was timely and accurate when posted. We are under no obligation to update or remove outdated information other than as required by applicable law or regulation.